Resverlogix Corp.

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. The company's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. Resverlogix can be followed on its blog at http://www.resverlogix.com/blog and via Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX

Expert Comments:

John Vandermosten, Zacks Equity Research (10/17/16)
"On October 13, 2016 Resverlogix Corp. held a research and development update for shareholders, investors and analysts in New York City. Several key opinion leaders and Resverlogix management team members spoke at the event providing an update on the latest thoughts on diabetes, chronic kidney disease and how these co-morbidities impact cardiovascular disease. . .we found the R&D update and KOL presentation very helpful in providing further understanding to the investment community of the opportunity for apabetalone and the company's epigenetic pipeline. Resverlogix has identified six different pathways where apabetalone has shown promise in improving MACE."

John Vandermosten, Zacks Equity Research (9/22/16)
"Resverlogix Corp. has increased the pace of investment into its portfolio of indications for apabetalone in recent quarters, launching a Phase 1 PK study with patients suffering from severe renal impairment and accelerating the pace of its BETonMACE study. We anticipate that the company will continue to launch studies in other neighboring indications as funding permits. . .we believe that durable patent position and the forecasted pricing of apabetalone, combined with a management skill set surrounding CVD and diabetes and a novel approach to addressing the residual risk in high need CVD patients, support our price target."

With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications.
read more >
John Vandermosten, Zacks Equity Research (7/29/16)
"Resverlogix Corp.'s lead product candidate, apabetalone, is the first selective BET bromodomain inhibitor in clinical trials for high-risk vascular disease. In the current Phase 3 BETonMACE trial, Apabetalone is targeting a very specific patient population with low HDL, type diabetes mellitus and chronic kidney disease with a high cardiovascular risk for increased MACE. . .Resverlogix is based on a large and growing underserved market in cardiovascular disease. With a growing older population in the world. . .the addressable market for therapies that reduce cardiovascular risk is increasing. . .we believe the company is undervalued."

John Vandermosten, Zacks Small-Cap Research (6/29/16)
"Resverlogix Corp. began recruiting and dosing participants in the Phase 3 BETonMACE trial of its lead candidate apabetalone (RVX-208) in high-risk CVD patients with diabetes in November 2015. . .with a potential impact on multiple markers for CVD we are optimistic on a materially significant impact on MACE. . .we view Resverlogix shares as undervalued, and in a position to provide long-term upside potential. We initiate RVX at CAD$5.00 per share and believe that expansion into new geographies, the orphan disease program, and renal disease, could provide further upside to our valuation."

Marcel Wijma, Van Leeuwenhoeck Research (5/11/16)
"We believe Resverlogix is substantially undervalued. . .we have increased our valuation to CAD8.50 from CAD5.85 per share. This represents a substantial upside from the current share price. . .the increase in valuation is based on the successful licensing deal with Shenzhen Hepalink Pharmaceutical Co., the initiation of the Phase III clinical trial BETonMACE as well as the commencement of other clinical research programs with apabetalone, specifically in orphan diseases. . .with a successful Phase III trial and considering the market potential for RVX-208, we feel that a very significant upside potential for RVX-208 and Resverlogix is attainable."

"Resverlogix Corp. is an interesting resurrection story. Its lead drug, RVX-208 (apabetalone), failed in a Phase 2b clinical trial back in 2013, but then the company discovered a couple of very interesting things about the compound. Now it better understands the mechanism of action of RVX-208, which is an epigenetic inhibitor. The drug is an inhibitor of BET (bromodomain and extraterminal) domains and it was shown to increase levels of apolipoprotein A1 (ApoA1), which is a component of high-density lipoproteins (HDL/good cholesterol). This is a classic example of how a company can design a new trial from what was learned in a failed trial. Instead of giving up after the failed 324-patient Phase 2b ASSURE trial in 2013, Resverlogix made adjustments to increase its chances of success. It started a big Phase 3 trial this past October in high-risk, type 2 diabetes patients with coronary artery disease. The primary endpoint is time to first occurrence of a major cardiovascular event (MACE), with expectations that RVX-208 will also increase HDL-C, ApoA1, and large HDLs and HDL particle size. Fittingly, this Phase 3 trial is called BETonMACE. Now, after seeing the complete data set from ASSURE and other studies of RVX-208, a lot of key opinion leaders are behind the drug candidate. What's interesting about Resverlogix is that it has a whole platform behind this BET domain inhibitor story. Given its history, the issue for the company now is how to regain the confidence of Wall Street, which has memory of the failed ASSURE trial. The most likely way is with positive clinical trial data. . .Resverlogix has some independent Data and Safety Monitoring Board (DSMB) looks scheduled. . .the company is in a lower market-cap slot right now, and obviously, if and when it gets up above $250M or $500M, more institutions will jump in." read more >

More Expert Comments

Experts Following This Company

John Vandermosten, CFA – Zacks Small-Cap Research
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research
George Zavoico, Senior Equity Analyst – JonesTrading

The information provided above is from analysts, newsletters, the company and other contributors.

Resverlogix Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
Phase 3 Status from European Regulatory Authority for BETonMACE Clinical Trial
Combination Licensing and Equity Arrangement with China-Based Shenzhen Hepalink Pharmaceutical Co., Ltd.
Two Patents for RVX-208 in China